

PPMI AV-133 Prodromal Imaging Substudy
Adverse Event In-Clinic Assessment

Complete this form at a visit that includes a PET imaging procedure to assess for adverse events.

A. Assessment Date: ___ / ___ / ___ (mm/dd/yyyy)

1. Was a PET imaging scan conducted at this visit?

- No
- Yes

1a. If Yes, were adverse events assessed following the procedure(s)?

- No
- Yes

i. If No, please explain:

ii. If Yes, were any adverse events observed?

- No
- Yes

If question 1.a.ii is "Yes", document information on the Adverse Event Log.

PPMI AV-133 Prodromal Imaging Substudy
Adverse Event Telephone Assessment

Complete this form for the telephone follow up 2-3 business days following PET imaging procedure to assess for adverse events.

A. Assessment Date: ___ / ___ / ___ (mm/dd/yyyy)

1. Was a PET imaging scan conducted at this visit?

- No
- Yes

2. Was contact made during this telephone call?

- No
- Yes

2a. If no, indicate the reason:

- Phone disconnected/number no longer in service
- Messages for participant were not returned
- Participant moved/unable to locate
- Other, specify: _____

3. Were any adverse events reported by the participant?

- No
- Yes

If question 3 is "Yes", new adverse event(s) should be documented on the Adverse Event Log.

PPMI AV-133 Prodromal Imaging Substudy
Conclusion of Study Participation

The *Conclusion of Study Participation* form should be completed when a participant either completes study participation, decides to no longer participate in the study/withdraws consent, or has withdrawn/concluded the PPMI Clinical study.

A. Assessment Date: ___ / ___ / ___ (mm/dd/yyyy)

1. Date of conclusion of participation: ___ / ___ / ___ (mm/dd/yyyy)

2. Select a reason for conclusion of study participation:

- Completed study per protocol
- Transportation/Travel issues (ex: logistics or travel, moved away from study site)
- Burden of study procedures (other than travel)
- Family, care-partner, or social issues (such as work/job obligations)
- Non-compliance with study procedures
- Adverse event
- Decline in health
- Lost to follow up
- Other, please specify:

3. Did increasing PD disability contribute to the decision to withdraw from the PPMI AV-133 Prodromal Imaging Study?

- No
- Yes
- Not Applicable

PPMI AV-133 Prodromal Imaging Substudy
Documentation of Informed Consent

Form instructions: Document date participant signed consent as the “Assessment Date” below.

A. Assessment Date: ___ / ___ / ___ (mm/dd/yyyy)

1. Informed consent was discussed with participant and/or legally authorized representative for the PPMI 015 AV-133 Prodromal Imaging Study. Participant and/or legally authorized representative was given adequate time to read the informed consent, the opportunity to ask questions and consent was obtained prior to any study procedures being performed.

No Yes

Monitor responsibilities

- Verify site process for obtaining informed consent is adequate according to 21 CFR 56.109(c) and 28 (21 CFR 50.27).
- Current approved ICF(s) version(s) are signed.
- Informed consent was obtained by person authorized on site delegation log.

PPMI AV-133 Prodromal Imaging Substudy

Inclusion/Exclusion Criteria

All inclusion criteria must be marked “Yes” and all exclusion criteria must be marked “No” before proceeding to enrollment. Otherwise, complete “Screen Fail” CRF for this substudy.

A. Assessment Date: ___ / ___ / ___ (mm/dd/yyyy)

Inclusion Criteria:

1. A Prodromal PD participant confirmed eligible to proceed to PPMI Clinical Baseline visit.
 Yes No
2. Able to provide informed consent.
 Yes No
3. Women may not be pregnant, lactating or planning pregnancy during the study.
 - a. Includes a negative serum pregnancy test prior to Baseline ¹⁸F-AV-133 injection.
 - b. Includes a negative urine pregnancy test prior to injection of ¹⁸F-AV-133 on day of Baseline PET scan.
 - c. Women participating in the study must be of *non-childbearing potential* or be using a *highly effective method of birth control* 14 days prior to until at least 24 hours after the last injection of ¹⁸F-AV-133. Yes No

Exclusion Criteria:

1. Received any of the following medications that might interfere with ¹⁸F-AV-133 PET imaging: tetrabenazine (TBZ) or methylphenidate, reserpine, or amphetamine derivative, within 1 month prior to the Baseline ¹⁸F-AV-133 injection.
 No Yes
2. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation.
 No Yes

PPMI AV-133 Prodromal Imaging Substudy
Pregnancy Test

A. Assessment Date: ___ / ___ / _____ (mm/dd/yyyy)

B. Is participant a female of childbearing potential?

Yes No

1. If female of childbearing potential, was urine pregnancy test performed?

Yes No

If no, explain why:

1a. If pregnancy test performed, is the participant pregnant?

Yes No

1b. Was the pregnancy test result confirmed prior to ¹⁸F-AV-133 injection for PET scan?

Yes No Not Applicable

If no, explain why:

2. Was serum pregnancy test confirmed negative prior to **Baseline** Visit ¹⁸F-AV-133 injection for PET scan?

Yes No Not Applicable

PPMI AV-133 Prodromal Imaging Substudy
Report of Pregnancy

Note: If a pregnancy was confirmed as occurring within 30 days following AV-133 injection, document this in the database within 24 hours of notification.

A. Assessment Date: ___ / ___ / ___ (mm/dd/yyyy)

1. This is a report of pregnancy for which person?

- Female participant
- Female partner of participant

2. Is the pregnancy confirmed as occurring within 30 days following the AV-133 injection?

- No
- Yes
- Unknown

**PPMI AV-133 Prodromal Imaging Substudy
Screen Fail**

A. Assessment Date: ___/___/____ (mm/dd/yyyy)

1. Participant did not enroll in PPMI AV-133 Prodromal Imaging due to:

- Eligibility Criteria
- Participant declined participation prior to completing baseline visit

1a. Please select the reason for declining:

- Risks of Protocol
- Confidentiality issues
- Protocol too time intensive
- Changed mind about lumbar puncture
- Travel requirements
- Family or caregiver/informant advised declining
- Physician (other than Site Investigator) advised declining
- Enrolled in other study
- No longer interested
- Other

PPMI AV-133 Prodromal Imaging Substudy
VMAT-2 Imaging

Note: Women of childbearing potential must have a negative urine and serum pregnancy test result prior to the baseline imaging scan and must have a negative urine pregnancy test result prior to injection of a follow up imaging scan.

A. Assessment Date: ___ / ___ / ___ (mm/dd/yyyy)

Vital signs measured approximately 30 minutes prior to injection

1. Was a study physician present to evaluate the participant prior to injection?

Yes

No

If no, please explain:

2. Time vital signs measured prior to injection: ___:___ (24-hour clock)

To be taken after participant has been supine for 1-3 minutes:

3. Supine blood pressure: _____ / _____ mmHg (systolic/diastolic)

4. Supine heart rate: _____ beats per minute

5. Time of ¹⁸F-AV-133 injection: ___:___ (24-hour clock)

Vital signs measured approximately 15-30 minutes post-injection

6. Time vital signs measured after injection: ___:___ (24-hour clock)

To be taken after participant has been supine for 1-3 minutes:

7. Supine blood pressure: _____ / _____ mmHg (systolic/diastolic)

8. Supine heart rate: _____ beats per minute

9. Was AV-133 PET imaging scan completed?

Yes

No

If no, please explain:

10. Was a study physician (or designee) present to evaluate the participant prior to discharge?

Yes

No

If no, please explain:
